ABSTRACT-
In addition to binding to various types of dopamine receptors, neuroleptics also bind to serotonin receptors.
The binding of antipsychotic drugs to both these two groups of receptors is related, to some degree, to certain identical amino acids found in the same critical position in these two groups of receptors, as illustrated in Fig. 1 . For example, the key amino acid for the binding of amines (1), such as neuroleptics, is aspartic acid (D) in the transmembrane region 3, as shown in Fig. 1 . This same aspartic acid is also important for the binding of the neu rotransmitter amines, such as dopamine (1) and seroto nin.
Transmembrane region 5 contains a serine that is criti cal for the binding of agonists (1, 2), such as dopamine (also see Refs. in Ref.
3), and, presumably, serotonin.
Thus, the general three-dimensional structure of these receptors permits dopamine and/or serotonin to bind to transmembrane regions 3 and 5 (Ref. 4), as depicted in Fig. 2 .
The aspartic acid in transmembrane region 2 deter mines the sensitivity of the receptors to sodium ions, influences the existence of the high-affinity for the agonist, and thereby affects the G-protein-coupling of the receptor to adenylyl cyclase (5, 6).
Transmembrane region 7 of serotonin receptors S 1 D, S l Dbeta and S 1 E contains threonine (adjacent to trypto phan, W, see Fig. 1 ). The replacement of this threonine by asparagine enhances the affinity of these receptors for propranolol by 100 to 1000-fold, matching the affinity of S1A for propranolol (7-10).
Additional features on the molecular biology of these receptors may be found in other reviews on dopamine receptors (11) and serotonin receptors (12-14). Of all the amino acid variations summarized in Fig. 2  and Tables 1 and 2 , the only receptor variant that exhibits a significantly different sensitivity to drugs is the valine to-glycine variation at position 194 in the human dopa mine D4-receptor (3, 15). Although the sensitivity of this receptor to spiperone is the same as that for the common D4-receptor, the sensitivity of this variant to clozapine and olanzapine falls 100 to 1000-fold compared to the common D4-receptor (15). Moreover, this receptor vari ant apparently has no functional high-affinity state for dopamine, and, therefore, the receptor does not inhibit adenylate cyclase, unlike the common D4-receptor (15). The "intrinsic" dissociation constant
It is possible to remove the dependence of the neuro leptic K on the ligand and thus obtain the intrinsic dis sociation constant of the neuroleptic in the absence of any competing ligand. This is done by extrapolating the rela tion shown (Fig. 4) down to the intercept on the vertical axis (i.e., at low partition coefficient). This intercept represents the intrinsic dissociation constant of the neu roleptic in the absence of any competing ligand. Thus, a low partition or a partition of "zero" indicates that the neuroleptic would be competing against a water-soluble ligand with low or negligible partition and which would be readily displaced by the neuroleptic.
Several examples of this are in Fig. 4 . The extrapolated or intrinsic K value for clozapine at D4 is 1.6 nM, in agreement with the Kd value of 1.5 nM as directly meas ured with [3H]clozapine at D4 (see Fig. 4 ). This value also agrees with that found (30, 31) for a D4-like site labelled by [3H]clozapine in rat frontal cortex. The present cloza pine intrinsic K value of 1.5 1.6 nM is significantly lower than the value of 6 nM reported for a [3H]clozapine binding site in rat brain membranes (32).
The A summary of the intrinsic K values for 17 neuroleptics at the dopamine D2 (cloned)-, D4 (cloned) and serotonin 2A (rat cortex)-receptors is given in Table 3 . Table 3 indicates that the neuroleptics fall into two groups, those that bind "loosely" and have high intrinsic K values at D2 (between 30 and 88 nM) and those that bind tightly to D2 with low intrinsic K values of 0.3 to 6 nM. An example of the usefulness of the intrinsic K is that it may be used to derive the therapeutic concentration of a neuroleptic. For example, although This approximate synaptic concentration of 4.2 nM clozapine, however, only applies for the blockade of 50% of the D4-receptors. Hence, the synaptic concentration of clozapine required to block 75% of the D4-receptors will be three times higher, or about 13 nM. [Actually, the clinical requirement to block 75% of the dopamine receptors to achieve antipsychotic action applies to the occupation of D2-receptors ( These considerations (as well as those below in Parkin son's disease) provide further support for the idea that clozapine is clinically operative at the dopamine D4 receptor, despite the fact that clozapine is known to bind to many receptors. methoxy-4-(methylamino)benzamide and consists of 50% of the R,R form and 50% of the S,S form, both forms being equally potent at the dopamine D2-receptor (with dissociation constants of about 14 to 76 pM, depending on which [3H]ligand is used). YM-09151-1 refers to the trans forms, both of which (i.e., R,S and S,R) have dissociation constants that are about 10-fold higher than YM-09151-2 at the D2-receptor (M. Terai, Yamanouchi Pharmaceutical Co., Japan, personal communi cation). The data in Fig. 4 (Fig. 4) , therefore, are qualitatively in agreement with the positron emission tomography findings.
Receptor bases for atypical neuroleptic action
The different receptor hypotheses, mentioned above, for the clinically atypical action of the atypical neurolep tics may be examined using the intrinsic K values. The first group are those atypical neuroleptics that have low affinity at D2 and thus may be readily displaced by high endogenous concentrations of dopamine in the caudate/putamen. This group includes remoxipride, clozapine, perlapine, seroquel and melperone, all of which have intrinsic K values in the higher range of 30 to 88 nM (Table 3) . This is in contrast to most typical neu roleptics that have intrinsic K values in the lower range of 0.3 to 6 nM (Table 3) . Molindone is borderline, having an intrinsic K value of 6 nM ( It is reasonable to expect, moreover, variations in the synaptic dopamine concentration in different brain regions, based on the different concentrations of homovanillic acid (HVA) found in these various regions. For example, the basal concentration of HVA in the rat striatum is 4 times higher than that in the limbic region (56) and 20 times higher than that in the pre-frontal cor tex (57) .
Hence, loosely bound neuroleptics (with high dissocia tion constants) would occupy more dopamine receptors in brain regions having low dopamine output (limbic regions, hypothalamus and pre-frontal cortex), but would occupy fewer dopamine receptors in regions hav ing high dopamine output (caudate/putamen) as a result of the neuroleptic competition with endogenous dopa mine (see Fig. 5, top) . Loose neuroleptics, therefore, would be expected to occupy a lower fraction of dopa mine receptors in the caudate/putamen but a higher frac tion in the nonstriatal regions, with corresponding fewer extrapyramidal signs compared to the typical neuroleptics with low intrinsic K values. These considerations may ex plain why seroquel (450 mg) occupies only 27% to 44010 of the D2-receptors in patients (using ["C]raclopride, Ref. 58 ) and why clozapine occupies only 48% of the D2 receptors in patients (using [11C]raclopride; 35, 38, 39), compared to the typical neuroleptics that occupy 70% to 80% of the D2-receptors (35, 38, 39). Although this low D2 occupancy with seroquel or clozapine matches their loose attachment to D2, two other loose atypical neuroleptics (melperone and remox ipride) occupy 70% of the D2 sites (35).
It would appear, therefore, that some loose neurolep tics (seroquel and clozapine) reveal low D2 occupancy, while other loose neuroleptics (melperone and remox ipride) reveal high D2 occupancy. This apparent incon sistency may be resolved by considering Fig. 5 (bottom) . This figure proposes two components within the 70% population of D2 sites that are not accessible to ["C] raclopride. One component consists of D2 sites that are occupied by the nonradioactive neuroleptic on which the patient is being maintained. The second component of D2 sites is that which is occupied by endogenous dopamine, occupying the high-affinity state of D2 with a dissociation constant of about 6 nM. This latter component may be of the order of 10% (35, 59) in healthy adults, as indicated by the intravenous administration of amphetamine which results in the displacement of ["C]raclopride (35, 59 ). This component is approximately 20% in schizophrenia patients (59) . It is proposed, therefore, that both loose and tight neuroleptics may prevent ["C]raclopride from occupying 70% of the D2 sites, except that the proportion of the two components just mentioned may vary, as illus trated in Fig. 5 (bottom) .
Combined block of D2 and muscarinic receptors
A second small group of two atypical neuroleptics, clozapine and thioridazine, strongly block both D2 and muscarinic receptors. Clozapine, for example, is of the order of 20 to 50-fold more potent in blocking muscar inic acetylcholine receptors than blocking dopamine D2 receptors (see Refs. in Ref. 60). Clozapine blocks mus carinic receptors at about 15 nM. Because anticholinergic drugs have an anti-Parkinson action, it might appear that the low value of 15 nM may readily account for the atypi cal action of clozapine. However, isoclozapine is equally anticholinergic (K of 11 nM, Ref. 61), yet elicits catalepsy in animals at low doses, in contrast to clozapine. Moreover, it has been argued that the combination of antagonists for dopamine (i.e., neuroleptic) and acetyl choline (i.e., benztropine) is not as effective in minimizing parkinsonism as clozapine itself (62).
Thioridazine also blocks muscarinic receptors at about the identical concentrations that it blocks D2-receptors (see Refs. in Ref. 60). Thus, the relatively low level of parkinsonism caused by thioridazine may stem from its anticholinergic action.
Combined block of D2 and serotonin S2A-receptors
A third mechanism that may account for the clinically atypical action of atypical neuroleptics is that these drugs may simultaneously block both D2 and serotonin S2A receptors (22-25).
The blockade of serotonin receptors increases the release of dopamine, as measured indirectly by the fall in ["C]raclopride binding to D2-receptors (63-65; see additional Refs. on dopamine-serotonin interactions in Ref.21). In turn, therefore, the increased release of endogenous dopamine displaces some of the neuroleptic from the D2-receptors, thereby partly alleviating the parkinsonism caused by the D2 blockade.
This mechanism (of enhancing dopamine release) may explain the modest alleviation of neuroleptic-induced catalepsy (in rats) by ritanserin, a serotonin antagonist (66). This alleviation only occurs, however, if the catalepsy is submaximum (66), but not if the catalepsy is maximum as produced by a relatively high dose of haloperidol (67, 68).
Ritanserin has been reported to alleviate neuroleptic induced parkinsonism and akathisia in patients (69, 70). However, ritanserin does not alleviate haloperidol-in duced dystonia in monkeys, unlike clozapine, which is very effective in reversing this extrapyramidal syndrome (71-74).
A more effective alleviation of neuroleptic-induced catalepsy is produced by 8-hydroxy-2-dipropylamino tetralin (8-OH-DPAT), a serotonin SIA agonist (67, 75-80).
There is mixed evidence, therefore, supporting the concept of a balanced block of D2 and serotonin S2A receptors to account for the low level or absence of parkinsonism by clozapine and other atypical neuroleptics.
In order to investigate this important D2/S2A block hypothesis further, the above intrinsic K values (Table 3) may be used for these two receptors. The intrinsic K values at the S2A-receptor are approximately the same as those reported by others for the neuroleptic dissociation constants at this receptor, using [3H]ketanserin (81, 82).
In principle, the ratio of the neuroleptic intrinsic K values for these two receptors should be related to the dose that elicits either parkinsonism in patients or catalepsy in rats. Such doses vary considerably, depend ing on how the parkinsonism or the catalepsy is meas ured.
For purposes of testing the D2/S2A hypothesis, there fore, the catalepsy doses as obtained in a single labora tory are more useful. Figure 6 (top), therefore, attempts to relate the intrinsic K values for the D2/S2A ratio with the rat catalepsy doses for various neuroleptics using catalepsy doses from a single laboratory (83) wherein the same criteria were used to measure catalepsy for all the neuroleptics tested.
In examining Fig. 6 (top) , it is important to note that clozapine and isoclozapine have almost identical selectiv ity for the S2A-receptor (compared to D2). Nevertheless, isoclozapine elicits catalepsy at about 3 mg/kg, while clozapine does not produce catalepsy at 100 mg/kg.
There is a trend toward a correlation between the rat catalepsy doses and the D2/S2A ratios of the intrinsic K values, as indicated by the dashed line in Fig. 6 . This trend would agree with other studies which have found a difference between typical and atypical neuroleptics in their relative occupancy of D2 and S2-receptors (84 87).
Drug selectivity for receptors is ligand-dependent: The data for olanzapine (Fig. 4) show that olanzapine is selec tive for the D4-receptor (compared to D2 or S2A), when using the intrinsic K values. However, if only the data for olanzapine using [3H]spiperone were considered, then olanzapine would be viewed as selective for the serotonin S2A-receptor (see Fig. 4) .
The receptor selectivity of haloperidol and isoclozapine (Fig. 4) are also dependent on the ligand considered. Clozapine, the most atypical neuroleptic, is also potent at many other receptors, including serotonin SIC (88, 89), S5 and S6-receptors (32, 42, 90), and a,-adrenocep tors (91), but not potent at serotonin S3-receptors (92). It is possible, therefore, that such other receptor sites con tribute to the atypical action of clozapine.
Selective block of dopamine D4-receptors
A fourth possible mechanism for atypical neuroleptic . Although clozapine and isoclozapine have identical D2/S2A ratios, the catalepsy dose for clozapine is in excess of 100 mg/kg (arrow). Bottom: Same as above (top) except that the catalepsy doses are graphed versus the ratio of the neuroleptic intrinsic K values for the D2 and D4-receptors (from Table 3 ). Thus, the horizontal axis indicates the neuroleptic selectivity for D4 relative to that for D2. The catalepsy doses were obtained in the laboratory of R. Corbett, except those for isoloxapine (Isolox.) (123) (124) (125) . Thioridazine (Thior.) is drawn differently (dotted lines) because it is a very potent anticholinergic drug; its anticataleptic action, therefore, may be attributed to its anticholinergic efficacy. Ilo. is iloperidone; Perl. is perlapine; Raclo. is raclopride; Cloz. is clozapine; Isocloz. is isoclozapine; Lox. is loxapine; Halo. is haloperidol; CPZ is chlorpromazine; Risper. is risperidone; and Mol. is molindone.
Roth et al. (93) have also found that perlapine, olanz apine and clozapine are selective for the dopamine D4 receptor, compared to the D2-receptor.
Although sertindole is only now beginning to be tested in large numbers of patients, it has been reported that sertindole does not elicit parkinsonism (94). The low level or absence of extrapyramidal signs with sertindole ap pears related to its ability to block D4-receptors more selectively than D2-receptors (Fig. 4 and 
